Clinical trials · Massachusetts
Recurrent Acute Myeloid Leukemia clinical trials in Massachusetts
We’re tracking 13 recruiting recurrent acute myeloid leukemia studies with a site in Massachusetts — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies in Massachusetts
- NCT03471260RecruitingPhase 1/Phase 2
Ivosidenib and venetoclax for IDH1-mutated leukemia or MDS
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
Boston, MassachusettsAges 18 years+ - NCT04024761RecruitingPhase 1
NK cell therapy for leukemia relapse after transplant
This Phase 1 study tests whether an infusion of special immune cells (NK cells) from a donor can help control leukemia or related blood cancers that come back or do not fully go away after a stem cell transplant. It also uses short chemotherapy to “make space” for the NK cells to work, and IL-2 to help them function.
Boston, MassachusettsAges 12 years+ - NCT04678401RecruitingPhase 1
Trial tests transplant using a half-matched donor for high-risk leukemia
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
Boston, MassachusettsAges 18–75 - NCT05143996RecruitingPhase 1
First study drug for relapsed AML or MDS
This Phase 1 trial tests CLN-049 in adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has come back or did not respond to treatment. The goal is to find out how well the drug can work and how safe it is in people with limited options.
Boston, MassachusettsAges 18 years+ - NCT05735184RecruitingPhase 1
Ziftomenib with AML medicines for NPM1- or KMT2A-mutated leukemia
This Phase 1 trial tests how safe and tolerable ziftomenib is when combined with standard AML medicines (like venetoclax and azacitidine, and other chemo options) in people with AML. It’s for AML patients who have specific genetic changes (NPM1 mutation or KMT2A rearrangement) and helps doctors find the best, safest dose plan.
Worcester, MassachusettsAges 18 years+ - NCT06152809RecruitingPhase 1
NK cell therapy plus venetoclax for high-risk AML
This trial tests an experimental NK cell therapy (CIML NK cells) given together with venetoclax for people with AML that has high-risk features or is not fully cleared by current treatment. It aims to stop the leukemia from coming back.
Boston, MassachusettsAges 18 years+ - NCT06247787RecruitingPhase 1
Imetelstat plus chemo for relapsed leukemia in kids
This trial tests a new drug called imetelstat combined with two chemotherapy drugs (fludarabine and cytarabine) for children and teens with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) that has come back or not responded to treatment. The goal is to find the safest dose of imetelstat and see if it helps control the cancer.
Boston, MassachusettsAges 1–18 - NCT06440135RecruitingPhase 1
Ziftomenib maintenance after stem cell transplant for AML
This trial tests if the drug ziftomenib can help prevent AML from coming back after a stem cell transplant. It is for people who have certain gene changes (KMT2A rearrangement or NPM1 mutation) and are in remission or near-remission before transplant.
Boston, MassachusettsAges 18 years+ - NCT06484062RecruitingPhase 1
Testing cirtuvivint alone and with ASTX727 for leukemia and MDS
This trial tests a new drug called cirtuvivint, given alone or with another drug (ASTX727), for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that has come back or not responded to treatment, and for people with high-risk MDS who have not been treated before. The goal is to see if these combinations work better than current options.
Boston, MassachusettsAges 18 years+ - NCT06660368RecruitingPhase 2
A study of a drug combo for relapsed or refractory AML
This trial tests a combination of targeted therapy (venetoclax) and chemotherapy (cladribine, cytarabine, G-CSF, mitoxantrone) for people with acute myeloid leukemia that has come back or not responded to previous treatment. It aims to see if this combination can help achieve remission.
Boston, MassachusettsAges 18–80 - NCT06994676RecruitingPhase 1
Study of CBX-250 for advanced myeloid leukemias
This study tests an experimental drug, CBX-250, for people with certain advanced blood cancers (like AML) that have not responded to standard treatments or have returned. The drug works only for people who have a specific genetic marker (HLA-A*02:01). The goal is to see if it is safe and how well it works.
Boston, MassachusettsAges 12 years+ - NCT07374029RecruitingPhase 1
T cell therapy with vaccine, decitabine, and venetoclax in AML
This trial tests a treatment that combines a personalized vaccine made from your leukemia cells and your own immune cells (T cells) with standard chemotherapy drugs (decitabine and venetoclax). The goal is to help your immune system better fight the leukemia.
Boston, MassachusettsAges Any age - NCT06707493RecruitingPhase 2
Ivosidenib after stem cell transplant for IDH1-mutated AML
This study tests whether a daily pill called ivosidenib can help prevent AML from coming back after a stem cell transplant. It is for people whose AML has a specific IDH1 gene change and who are planning to have a transplant.
Boston, MassachusettsAges 18–75
Recurrent Acute Myeloid Leukemia trials by city in Massachusetts
Where these studies are running in Massachusetts
Institutions with a site for the recruiting recurrent acute myeloid leukemia studies listed above.
- Dana-Farber Cancer Institute · 9 studies
- Massachusetts General Hospital · 4 studies
- Beth Israel Deaconess Medical Center
- Boston Children's Hospital
- Brigham and Women's Hospital
- University of Massachusetts Chan Medical School
What taking part in a recurrent acute myeloid leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Recurrent Acute Myeloid Leukemia trials in other states
Common questions
- Are there recurrent acute myeloid leukemia clinical trials in Massachusetts?
- Yes. We're currently tracking 13 recruiting recurrent acute myeloid leukemia studies with a site in Massachusetts, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a recurrent acute myeloid leukemia study in Massachusetts?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Massachusetts to take part?
- Not necessarily. These studies have a site in Massachusetts, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a recurrent acute myeloid leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New recurrent acute myeloid leukemia studies open in Massachusetts regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.